Evidence map›Paper›PMID 32122317›Full record

ArticleBMC infectious diseases2020

Comprehensive proteomics investigation of P. vivax-infected human plasma and parasite isolates.

Apoorva Venkatesh, Shalini Aggarwal, Swati Kumar, Srushti Rajyaguru, Vipin Kumar, Sheetal Bankar, Jayanthi Shastri, Swati Patankar, Sanjeeva Srivastava

Open access · goldAbstract read
In one paragraph

Article in BMC infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Multi-Omics Advancements towardsDiagnostics (Basel, Switzerland) · 2021
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Apoorva VenkateshDepartment of Biosciences and Bioengineering, Indian Institute of Technology Bombay, Powai, Mumbai, India.
Shalini AggarwalDepartment of Biosciences and Bioengineering, Indian Institute of Technology Bombay, Powai, Mumbai, India.
Swati KumarDepartment of Biosciences and Bioengineering, Indian Institute of Technology Bombay, Powai, Mumbai, India.
Srushti RajyaguruDepartment of Biosciences and Bioengineering, Indian Institute of Technology Bombay, Powai, Mumbai, India.
Vipin KumarDepartment of Biosciences and Bioengineering, Indian Institute of Technology Bombay, Powai, Mumbai, India.
Sheetal BankarDepartment of Microbiology, T. N. Medical College and BYL Nair Hospital, Mumbai, India.
Jayanthi ShastriDepartment of Microbiology, T. N. Medical College and BYL Nair Hospital, Mumbai, India.
Swati PatankarDepartment of Biosciences and Bioengineering, Indian Institute of Technology Bombay, Powai, Mumbai, India.
Sanjeeva SrivastavaDepartment of Biosciences and Bioengineering, Indian Institute of Technology Bombay, Powai, Mumbai, India. sanjeeva@iitb.ac.in.ORCID http://orcid.org/0000-0001-5159-6834
Indian Institute of Technology Bombay · INTopiwala National Medical College & BYL Nair Charitable Hospital · IN

Funding

Department of Biotechnology BT/PR12174/MED/29/888/2014
6 · The paper itself

Abstract

backgroundIn recent times, Plasmodium vivax (P. vivax) has become a serious threat to public health due to its ability to cause severe infection with fatal outcomes. Its unique biology makes it resilient to control measures that are otherwise effective against P. falciparum. A deeper understanding of P. vivax biology and pathogenesis is, therefore, essential for developing the right control strategies. Proteomics of P. falciparum has been helpful in studying disease biology and elucidating molecular mechanisms involved in the development of disease. However, unlike P. falciparum, proteomics data for P. vivax infection is minimal due to the absence of a continuous culture system. The dependence on clinical samples and animal models has drastically limited P. vivax research, creating critical knowledge gaps in our understanding of the disease. This study describes an in-depth proteomics analysis of P. vivax-infected human plasma and parasite isolates, to understand parasite biology, pathogenesis, and to identify new diagnostic targets for P. vivax malaria.

methodsA mass-spectrometry- (MS) based proteomics approach (Q Exactive) was applied to analyze human plasma and parasite isolates from vivax malaria patients visiting a primary health centre in India. Additionally, a targeted proteomics assay was standardized for validating unique peptides of most recurring parasite proteins.

resultsThirty-eight P. vivax proteins were detected in human plasma with high confidence. Several glycolytic enzymes were found along with hypothetical, cytoskeletal, ribosomal, and nuclear proteins. Additionally, 103 highly abundant P. vivax proteins were detected in parasite isolates. This represents the highest number of parasite proteins to be reported from clinical samples so far. Interestingly, five of these; three Plasmodium exported proteins (PVX_003545, PVX_003555 and PVX_121935), a hypothetical protein (PVX_083555) and Pvstp1 (subtelomeric transmembrane protein 1, PVX_094303) were found in both plasma and parasite isolates.

conclusionsA parasite proteomics investigation is essential to understand disease pathobiology and design novel interventions. Control strategies against P. vivax also depend on early diagnosis. This work provides deeper insights into the biology of P. vivax by identifying proteins expressed by the parasite during its complex life-cycle within the human host. The study also reports antigens that may be explored as diagnostic candidates.

Indexed as

Gene OntologyHost-Parasite InteractionsHumansIndiaLife Cycle StagesMalaria, VivaxPlasmodium vivaxProteomicsProtozoan ProteinsTandem Mass SpectrometryProtozoan ProteinsBiomarkersDiagnosisMass spectrometryParasite biologyPlasmaP. vivax

Identifiers

PMID32122317
PMCPMC7053139
OpenAlexW3012164255

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.